Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto

Abstract

Keywords

COVID-19 psoriasis dupilumab dermatology

Get full access to this article

View all access options for this article.

References

Johns Hopkins Coronavirus Resource Center . COVID-19 Case Tracker. Johns Hopkins University and Medicine. Accessed April 15, 2020. https://coronavirus.jhu.edu/. Published 2020

Ferrucci

Romagnuolo

Angileri

Berti

Tavecchio

. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol. 2020;16527. doi:10.1111/jdv.16527

http://www.ncbi.nlm.nih.gov/pubmed/32330323

Simpson

EL.

Bieber

Guttman-Yassky

et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020

http://www.ncbi.nlm.nih.gov/pubmed/27690741